文献

重组抗小鼠PD-1单克隆抗体(克隆号RMP1-14.1) ，大鼠IgG2a Kappa（Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone: RMP1-14.1), Rat IgG2a Kappa，货号：PA007504.r2a Syd Labs）

大鼠抗小鼠PD-1单克隆抗体（克隆号RMP1-14，大鼠IgG2a kappa）可与由小鼠pdcd1基因编码的小鼠PD-1蛋白（CD279或程序性死亡-1）发生反应，该蛋白是免疫球蛋白超家族CD28家族的成员。PD-1有两个配体，即PD-L1和PD-L2，两者均属于B7家族。研究表明，在黑色素瘤小鼠模型中，通过抗小鼠PD-1抗体和抗小鼠PD-L1抗体进行治疗可以阻断PD-L1蛋白与其受体PD-1蛋白之间的相互作用，从而使肿瘤生长得到暂时性抑制。RMP1-14抗体能够阻断小鼠PD-L1蛋白和小鼠PD-L2蛋白与小鼠PD-1蛋白的结合。

我们的重组RMP1-14抗体包含大鼠抗小鼠PD-1抗体（杂交瘤克隆名称或编号：RMP1-14）的部分（可变区）或完整的氨基酸序列。这种鼠源化抗小鼠PD-1重组抗体不仅具有小鼠IgG抗体的恒定区，还具有鼠源化的可变区。

CD279抗体（RMP1-14抗体、抗小鼠PD-1单抗）流式部分参考文献:

1. A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies.
Bu, M. T., et al. Monoclon Antib Immunodiagn Immunother. 2022 Aug;41(4):202-209. PMID: 35925787
“Unconjugated and fluorophore-conjugated PD-1 mAbs (1A12, rat IgG2a; RMP1-14, rat IgG2a; and RMP1-30, rat IgG2b) and PD-L1 mAbs (10F.9G2, rat IgG2b; MIH6, rat IgG2a) were purchased from…Owing to the widespread use of both PD-1 mAbs 1A12 and RMP1-14 in experimental mouse models, we compared the avidities of these two mAbs. …The 1A12 antimouse PD-1 mAb bound to mPD-1–transfected Jurkat cells in a dose-dependent manner with an apparent affinity of 0.42 nM, while RMP1-14 antibody bound with a much weaker apparent affinity of 28.8 nM…”

2. Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies.
Metzger, P., et al. Sci Rep. 2018 Jun 11;8(1):8810. PMID: 29892077
“We assessed PD-1 expression by flow cytometry and compared the two mainly used antibody clones (29 F.1A12 and RMP1-14 antibodies), which were also included in the above-mentioned study. …We observed PD-1 staining exclusively in the dead cell fraction for both clones 29 F.1A12 and RMP1-14 mAb, respectively…”

3. The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent.
Grasselly, C., et al. Front Immunol. 2018 Oct 9;9:2100. PMID: 30356816
“Anti-PD1 antibody(clone RMP1-14) or anti-PDL1 (clone 10F.9G2) mAb (12,5 mg/kg, ip, q1wk) were administered in combination with (A,C) methotrexate (1 mg/kg, ip, q1wk), vinblastine (0.1 mg/kg, ip, q1wk), doxorubicin(1 mg/kg, ip, q1wk) and cisplatin(1 mg/kg,ip, q1wk, MVAC) in SC bladder cancer MB49 and MBT-2, and with (B) cyclophosphamide (CTX, 100 mg/kg, ip, q1wk) and doxorubicin (DOX, 2 mg/kg, ip, q1wk) in SC metastatic breast cancer 4T1…”

4. Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma.
DeAzevedo, R., et al. J Immunother Cancer. 2024 Oct 30;12(10):e009690. PMID: 39477243
“On days 7, 11, 15, and 19, mice received 250 ug anti-PD-1 antibody RMP1-14 i.p. or isotype control antibody. …On days 7, 11, 15, and 19, mice received 250 ug anti-PD-1 mAb RMP1-14 i.p. or isotype control antibody. …In this system, mice were treated when measurable tumors emerged with 10 doses of c-Met inhibitor and 5 doses of the PD-1 antibody RMP1-14…”

5. Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy.
Denis, M., et al. Front Immunol. 2023 Jan 10;13:1011943. PMID: 36703964
“When the tumor volume reached 150 mm3, mice were randomized and received first treatment of anti-PD-1 antibody (RMP1-14, 12.5 mg/kg per week, intraperitoneal (IP)). …The mice are randomized based on their weight and receive 48 hours after the operation their first anti-PD-1 treatments (RMP1-14, 12.5 mg/kg per week, IP)…”